Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies SYDNEY, AUSTRALIA – 11 November 2026 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced the grant of a...
Immutep Expands US Patents for Efti Combination Therapies
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Immutep Ltd announced the grant of a new patent for Efti-based combination therapies by the United States Patent and Trademark Office. The CEO emphasized the importance of a strong patent portfolio for future development and partnership opportunities. Efti is a proprietary protein that activates immune responses and has received designations from the U.S. FDA for specific cancer treatments.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Immutep
- EFTISARC-NEO Survival Data reported in CTOS 2026 Abstract
- IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses
- IMP761 Late-Breaking Abstract at ACR shows T-Cell Inhibition
- Upcoming Poster Presentations at CTOS and ESMO IO 2026
- Immutep Quarterly Activities Report and Appendix 4C
Later from Immutep
- Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO
- Immutep Investor Update
- Encouraging Disease-Free Survival in Phase II Sarcoma Trial
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep